文献速递脑血管病

大缺血核心卒中血管内取栓的系统综述与荟萃分析

Endovascular Thrombectomy for Large Ischemic Core Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Neurology · 2025-04-17

该研究通过系统综述和荟萃分析6项随机对照试验共1887例大核心急性缺血性卒中患者,评估血管内取栓(EVT)与最佳药物治疗(BMT)的安全性和有效性。结果显示EVT改善90天mRS评分(广义OR 1.6,95%CI 1.4-1.8)并提高独立行走几率(RR 1.9,95%CI 1.5-2.5),虽症状性颅内出血风险增加(RR 1.7,95%CI 1.1-2.7),但死亡率降低(RR 0.9,95%CI 0.8-1.0)。

要点

  • EVT改善大核心卒中90天mRS(广义OR 1.6)及独立行走(RR 1.9)。
  • EVT组sICH风险增高(RR 1.7),但死亡率降低(RR 0.9)。
  • ASPECTS 0-2患者EVT仍与mRS 0-3(RR 2.1)和mRS 0-2(RR 2.8)改善相关。

核心结论

  • EVT改善ASPECTS 3-5或体积法评估的大核心AIS患者的临床结局。
  • ASPECTS 0-2患者也从EVT获益,需进一步研究。
  • 结果支持扩大EVT的常规应用。

研究设计与样本

  • 研究-level荟萃分析和meta回归,纳入6项比较EVT与BMT的RCT,共1887例大核心AIS患者。
  • 检索PubMed、Embase和Cochrane数据库(1980年1月1日至2024年6月30日)。
  • 使用PRISMA指南评估数据质量和有效性。

主要发现

  • EVT vs BMT:90天mRS改善(广义OR 1.6,95%CI 1.4-1.8)。
  • EVT vs BMT:独立行走(mRS 0-3)几率更高(RR 1.9,95%CI 1.5-2.5)。
  • EVT vs BMT:sICH风险更高(RR 1.7,95%CI 1.1-2.7),死亡率降低(RR 0.9,95%CI 0.8-1.0)。
  • Meta回归:EVT获益随OTR延长而下降(mRS 0-3斜率-0.11,95%CI -0.12至-0.10;mRS 0-2斜率-0.15,95%CI -0.16至-0.14)。
  • ASPECTS 0-2患者:EVT与90天mRS 0-3(RR 2.1,95%CI 1.4-3.3)和mRS 0-2(RR 2.8,95%CI 1.2-6.7)增加相关。

关键数值与推荐

  • 主要结局:90天序贯mRS。
  • 次要结局:90天独立行走(mRS 0-3)、sICH和死亡率。
  • EVT vs BMT的mRS 0-3的RR 1.9(95%CI 1.5-2.5),sICH的RR 1.7(95%CI 1.1-2.7),死亡率的RR 0.9(95%CI 0.8-1.0)。

临床怎么用

  • 对于大核心AIS(ASPECTS 3-5或体积法),EVT可改善临床结局。
  • ASPECTS 0-2患者也可从EVT获益,但需进一步研究。
  • 结果支持扩大EVT的常规应用。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The optimal management of acute ischemic stroke (AIS) patients with large vessel occlusion and large ischemic core is uncertain. We aimed to evaluate the safety and efficacy of endovascular thrombectomy (EVT) compared with best medical treatment (BMT) for AIS through a study-level meta-analysis and meta-regression of 6 randomized controlled trials (RCTs). METHODS: PubMed, Embase, and the Cochrane databases were searched from January 1, 1980, to June 30, 2024. We limited search results to RCTs which compared EVT vs BMT among large-core AIS. The Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline was used for abstracting and assessing data quality and validity. The risk ratio (RR) with 95% CI was used to measure the association of EVT vs BMT with outcomes. Univariable meta-regression analyses were conducted to evaluate possible moderating effects of onset to randomization time (OTR) on outcomes when comparing EVT with BMT. The primary outcome was the 90-day ordinal modified Rankin Scale (mRS). Secondary outcomes were independent ambulation (mRS 0-3) at 90 days, and symptomatic intracranial hemorrhage (sICH) and mortality at 90 days. RESULTS: Six RCTs comprising 1,887 patients with large core AIS were included. Pooled results showed that EVT compared with BMT was associated with improved mRS score at 90 days (generalized OR, 1.6, 95% CI 1.4-1.8) and higher odds of independent ambulation (RR 1.9; 95% CI 1.5-2.5). Although the risk of sICH was higher in the EVT group (RR 1.7; 95% CI 1.1-2.7), there was a reduction in mortality in the EVT group (RR 0.9; 95% CI 0.8-1.0). Meta-regression showed that the benefit of EVT decreased with the extension of OTR (mRS 0-3, regression slope, -0.11, 95% CI -0.12 to -0.10; mRS 0-2, regression slope, -0.15, 95% CI -0.16 to -0.14). For patients with Alberta Stroke Program Early CT Score (ASPECTS) 0-2, EVT was associated with increased 90-day mRS 0-3 (RR 2.1, 95% CI 1.4-3.3) and mRS 0-2 (RR 2.8, 95% CI 1.2-6.7). DISCUSSION: EVT improved clinical outcomes among patients with large-core AIS assessed by ASPECTS of 3-5 or volumetric methods. Patients with ASPECTS 0-2 also had benefit from EVT and require further study. These results support expansion of the routine application of EVT.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Liu C, Abdalkader M, Sang H, et al. Endovascular Thrombectomy for Large Ischemic Core Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Neurology. 2025. PMID: 40245349. doi:10.1212/WNL.0000000000213443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。